140
Participants
Start Date
December 4, 2024
Primary Completion Date
March 31, 2028
Study Completion Date
March 31, 2028
JNJ-79635322
JNJ-79635322 will be administered subcutaneously.
Daratumumab
Daratumumab will be administered subcutaneously.
Pomalidomide
Pomalidomide will be administered orally.
Lenalidomide
Lenalidomide will be administered orally.
RECRUITING
Calvary Mater Newcastle Hospital, Waratah
RECRUITING
Wollongong Hospital, Wollongong
RECRUITING
Peter MacCallum Cancer Centre, Melbourne
RECRUITING
St Vincents Hospital Melbourne, Fitzroy
RECRUITING
Monash Medical Centre, Clayton
RECRUITING
Hosp Clinico Univ de Salamanca, Salamanca
RECRUITING
Sheba Medical Center, Ramat Gan
RECRUITING
Tel Aviv Sourasky Medical Center, Tel Aviv
RECRUITING
Carmel Medical Center, Haifa
RECRUITING
Hadassah Medical Center, Jerusalem
RECRUITING
VU Medisch Centrum, Amsterdam
RECRUITING
Universitair Medisch Centrum Groningen, Groningen
RECRUITING
UMC Utrecht, Utrecht
RECRUITING
Hosp. Clinic de Barcelona, Barcelona
Janssen Research & Development, LLC
INDUSTRY